Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

Abstract Background KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to iden...

Full description

Bibliographic Details
Main Authors: Yafang Wang, Mingyue Yao, Cheng Li, Kexin Yang, Xiaolong Qin, Lansong Xu, Shangxuan Shi, Chengcheng Yu, Xiangjun Meng, Chengying Xie
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Experimental Hematology & Oncology
Subjects:
KRASG12C
c-Myc
PLK1
LncRNA
ST8SIA6-AS1
Drug resistance
Online Access:https://doi.org/10.1186/s40164-023-00466-3

Internet

https://doi.org/10.1186/s40164-023-00466-3

Similar Items